National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

99 -- STAINING REAGENTS SOL RFQ-NCI-00035-NR DUE 011000 POC Marsha Gorham, purchasing agent & Todd Cole, Contracting Officer The Hematopathology Section, Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute (NCI) plans on procuring immunohistochemical staining reagents and antibodies from Dako Corporation 6392 Via Real, Carpinteria, CA 93013 USA. This notice is issued in accordance with the commercial contracting and simplified acquisition procedures of FAR Parts 12 and 13. The Laboratory of Pathology currently offers tests using numerous reagents and antibodies. Each antibody that is used in the laboratory is subjected to rigorous quality control procedures that test the antibody's reactivity and sensitivity. Three-fourths of the antibodies in use within the Laboratory of Pathology are from Dako Corporration. The laboratory has been using Dako antibodies and products for over 10 years through various purchasing mechanisms (i.e., contracts, BPAs, etc.). The reagents are used for diagnostic immunohistochemistry laboratory clinical use as well as for supporting clinical and basic research in the Laboratory of Pathology. The primary Dako reagents and antibodies that have been used previously and that are required, include the following categories: 1) detection reagents, 2) high sensitivity polymer-based amplification systems, 3) high sensitivity non-radioactive amplification systems for immunohistochemical staining, 4) ancillary reagents, 5) antibodies, 6) secondary reagents, 7) negative control reagents, and 8) non-radioactive amplification systems for immunohistochemical staining. Furthermore, the high sensitivity non-radioactive amplification systems for immunohistochemical staining and the high sensitivity polymer-based amplification systems, along with other reagents/antibodies, are proprietary lines that can only be purchased through Dako. Changing vendors at this time would force the laboratory to retest and perform quality control procedures on all of the 75 or so antibodies traditionally ordered from Dako. Even if quality controls are met, the same antibody from other vendors may present differences in staining due to packaging differences (diluent or added carriers). Therefore, to maintain consistency in staining and in the interpretation of the slides, the Laboratory of Pathology must purchase the same antibodies from Dako. There is no other source known by the NCI researcher that can perform the above requirement. Based on laboratory usage, the anticipated award will have a minimum purchase limit of at least $29,000 with a maximum limit of $60,000 per year. A base period of one year with two, one year options is also anticipated. This is not a request for competitive quotation. However, if any interested party believes it can provide all of the above reagents, antibodies and supplies, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI researcher to determine if the party can provide the above items. Capability statements must be received in the contracting office by 2:00 p.m. (Local Time) on January 10, 2000 If you have any questions, please contact Marsha Gorham, Purchasing Agent on (301) 402-4509. A determination by the government not to compete this requirement based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Please reference RFQ-NCI-00035-NR on all correspondence and documentation. Posted 12/23/99 (W-SN411329). (0357)

Loren Data Corp. http://www.ld.com (SYN# 0154 19991228\99-0001.SOL)